These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34362796)

  • 1. Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
    Butler LM; Mah CY; Machiels J; Vincent AD; Irani S; Mutuku SM; Spotbeen X; Bagadi M; Waltregny D; Moldovan M; Dehairs J; Vanderhoydonc F; Bloch K; Das R; Stahl J; Kench JG; Gevaert T; Derua R; Waelkens E; Nassar ZD; Selth LA; Trim PJ; Snel MF; Lynn DJ; Tilley WD; Horvath LG; Centenera MM; Swinnen JV
    Cancer Res; 2021 Oct; 81(19):4981-4993. PubMed ID: 34362796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
    Centenera MM; Scott JS; Machiels J; Nassar ZD; Miller DC; Zinonos I; Dehairs J; Burvenich IJG; Zadra G; Chetta PM; Bango C; Evergren E; Ryan NK; Gillis JL; Mah CY; Tieu T; Hanson AR; Carelli R; Bloch K; Panagopoulos V; Waelkens E; Derua R; Williams ED; Evdokiou A; Cifuentes-Rius A; Voelcker NH; Mills IG; Tilley WD; Scott AM; Loda M; Selth LA; Swinnen JV; Butler LM
    Cancer Res; 2021 Apr; 81(7):1704-1718. PubMed ID: 33547161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer.
    Meller S; Meyer HA; Bethan B; Dietrich D; Maldonado SG; Lein M; Montani M; Reszka R; Schatz P; Peter E; Stephan C; Jung K; Kamlage B; Kristiansen G
    Oncotarget; 2016 Jan; 7(2):1421-38. PubMed ID: 26623558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cell's metabolic crosstalk.
    Altuna-Coy A; Ruiz-Plazas X; Sánchez-Martin S; Ascaso-Til H; Prados-Saavedra M; Alves-Santiago M; Bernal-Escoté X; Segarra-Tomás J; R Chacón M
    BMC Med; 2022 Aug; 20(1):255. PubMed ID: 35978404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
    Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
    Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
    Mohamed AA; Tan SH; Xavier CP; Katta S; Huang W; Ravindranath L; Jamal M; Li H; Srivastava M; Srivatsan ES; Sreenath TL; McLeod DG; Srinivasan A; Petrovics G; Dobi A; Srivastava S
    Mol Cancer Res; 2017 Oct; 15(10):1308-1317. PubMed ID: 28607007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer diagnosis and characterization with mass spectrometry imaging.
    Kurreck A; Vandergrift LA; Fuss TL; Habbel P; Agar NYR; Cheng LL
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):297-305. PubMed ID: 29209003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue and serum lipidome shows altered lipid composition with diagnostic potential in mycosis fungoides.
    Xu C; Zhou D; Luo Y; Guo S; Wang T; Liu J; Liu Y; Li Z
    Oncotarget; 2017 Jul; 8(29):48041-48050. PubMed ID: 28624795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipidomic Analysis of Cancer Cell and Tumor Tissues.
    Islam SR; Manna SK
    Methods Mol Biol; 2019; 1928():175-204. PubMed ID: 30725457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging.
    Randall EC; Zadra G; Chetta P; Lopez BGC; Syamala S; Basu SS; Agar JN; Loda M; Tempany CM; Fennessy FM; Agar NYR
    Mol Cancer Res; 2019 May; 17(5):1155-1165. PubMed ID: 30745465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid Uptake Is an Androgen-Enhanced Lipid Supply Pathway Associated with Prostate Cancer Disease Progression and Bone Metastasis.
    Tousignant KD; Rockstroh A; Taherian Fard A; Lehman ML; Wang C; McPherson SJ; Philp LK; Bartonicek N; Dinger ME; Nelson CC; Sadowski MC
    Mol Cancer Res; 2019 May; 17(5):1166-1179. PubMed ID: 30808729
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative lipidomics of azole sensitive and resistant clinical isolates of Candida albicans reveals unexpected diversity in molecular lipid imprints.
    Singh A; Prasad R
    PLoS One; 2011 Apr; 6(4):e19266. PubMed ID: 21559392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Proteome of Primary Prostate Cancer.
    Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
    Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shotgun lipidomics-based characterization of the landscape of lipid metabolism in colorectal cancer.
    Wang Y; Hinz S; Uckermann O; Hönscheid P; von Schönfels W; Burmeister G; Hendricks A; Ackerman JM; Baretton GB; Hampe J; Brosch M; Schafmayer C; Shevchenko A; Zeissig S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Mar; 1865(3):158579. PubMed ID: 31794862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface analysis of lipids by mass spectrometry: more than just imaging.
    Ellis SR; Brown SH; In Het Panhuis M; Blanksby SJ; Mitchell TW
    Prog Lipid Res; 2013 Oct; 52(4):329-53. PubMed ID: 23623802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling.
    Kim HY; Lee H; Kim SH; Jin H; Bae J; Choi HK
    Sci Rep; 2017 Aug; 7(1):8864. PubMed ID: 28821754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.
    Xiao Q; Sun Y; Dobi A; Srivastava S; Wang W; Srivastava S; Ji Y; Hou J; Zhao GP; Li Y; Li H
    Sci Rep; 2018 Aug; 8(1):12868. PubMed ID: 30150711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics.
    Zhou X; Mao J; Ai J; Deng Y; Roth MR; Pound C; Henegar J; Welti R; Bigler SA
    PLoS One; 2012; 7(11):e48889. PubMed ID: 23152813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
    Semaan L; Mander N; Cher ML; Chinni SR
    BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
    Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
    Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.